China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will ...
SHANGHAI (Reuters) - Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, ...
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the ...
Innovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli Lilly's diabetes and heart drug Trulicity when it came to glycemic control in patients with Type 2 ...
Eli Lilly & Co. said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced the severity of ...
Roche ROG-0.67%decrease; red down pointing triangle Holding said its weight-loss drug candidate achieved positive results in an early-stage trial, giving the company a boost in its bid to catch up ...
The diabetes and weight loss prescription drug market shows no sign of thinning out anytime soon. Tackling the obesity problem head-on has been tried before with fad diets and low-quality, low ...
Eli Lilly drug tirzepatide, marketed as Zepbound for weight management, has results from two Phase 3 studies showing reductions in the breathing problems caused by obstructive sleep apnea.
Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound ...
(Bloomberg) -- Eli Lilly & Co.’s shares soared as its brighter outlook for 2024 raised the potential ceiling for new weight-loss drugs even further in the eyes of analysts and investors. Most Read ...